AstraZeneca to withdraw Zoladex breast cancer and endometriosis treatment from Australian market in November
AstraZeneca is removing Zoladex (Goserelin 3.6mg), a breast cancer and endometriosis treatment, from Australia's Pharmaceutical Benefits Scheme and private market starting November, with existing patients able to access it for six additional months. The drug is used by approximately 7,000 Australian women annually with breast cancer and provides pain relief for endometriosis patients. The withdrawal is attributed to commercial reasons, likely related to AstraZeneca's shift toward manufacturing higher-dose formulations for prostate cancer patients.
AstraZeneca is discontinuing Zoladex (Goserelin 3.6mg implant) from the Australian market in November, affecting thousands of women who rely on the medication for breast cancer treatment and endometriosis management. The drug suppresses ovarian oestrogen production in hormone receptor-positive breast cancer patients and provides significant pain relief for endometriosis sufferers. Breast Cancer Network Australia estimates 7,000 women with breast cancer access the medicine annually, though 94,000 prescriptions were filled in the last 18 months. The company cited lack of commercial viability, with pharmaceutical chemistry experts suggesting the decision reflects AstraZeneca's preference for manufacturing the higher-dose 10.8mg formulation used for prostate cancer, which requires less frequent administration. Existing patients will retain access for an additional six months beyond November, but advocates warn the removal could be life-altering for women currently managing their conditions with the treatment.
What's missing
The article does not specify what alternative treatments are available for breast cancer patients or endometriosis sufferers in Australia, nor does it detail the timeline or process for patients to transition to alternative therapies. Additionally, AstraZeneca's specific response regarding alternative options for affected patients is not included.
What different sources said
Breast cancer and endometriosis drug Zoladex is being pulled from Australia. How will women be affected?
Related
Sydney Psychiatrist Retains Medical License After Sexual Assault Conviction
Gopi Ilawala, a Sydney psychiatrist convicted of sexually assaulting an intoxicated colleague in 2022, has been allowed to continue practicing medicine despite the state health regulator seeking to have his registration cancelled. The New South Wales Civil and Administrative Tribunal reprimanded him and imposed conditions rather than striking him off, citing his remorse, lack of prior convictions, and support from two senior psychiatrists. The decision raises questions about professional accountability and public protection in medical regulation.
Australia's TGA to crack down on illegal peptides; government allocates $100m for arthritis research
Australia's Therapeutic Goods Administration has announced a crackdown on illegal peptides due to a surge in imports and online advertising, designating them a priority focus area. The federal government has simultaneously committed $100 million to medical research into arthritis prevention, diagnosis, and treatment. These developments reflect growing regulatory concerns about unregulated drugs and increased investment in chronic disease research.
GLP-1 Drugs Like Ozempic May Help ADHD Symptoms, According to Patient Reports and Clinical Observations
Social media users and some patients are reporting that GLP-1 receptor agonist drugs like Ozempic appear to improve ADHD symptoms, including increased focus, reduced procrastination, and better impulse control. GLP-1s were originally developed to treat Type 2 diabetes but are being studied for various other conditions. While anecdotal reports are growing, no formal clinical trials are currently testing these drugs specifically for ADHD, and the mechanism behind any potential benefit remains unclear.